Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct 30;7(1):121-124.
doi: 10.1016/j.ekir.2021.10.018. eCollection 2022 Jan.

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra

Andrea Angeletti  1   2 , Alberto Magnasco  1 , AntonellaTrivelli  1 , Ludovica M Degl'Innocenti  1 , Giorgio Piaggio  1 , Francesca Lugani  2 , Gianluca Caridi  2 , Enrico Verrina  1 , Paolo Cravedi  3 , Gian Marco Ghiggeri  1   2
Affiliations
Case Reports

Refractory Minimal Change Disease and Focal Segmental Glomerular Sclerosis Treated With Anakinra

Andrea Angeletti et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proteinuria and serum creatinine levels in a patient with focal segmental glomerular sclerosis multidrug resistant. h, hour; HD, hemodialysis; IL-1R, interleukin-1 receptor; pCreat, creatinine in patient.
See this image and copyright information in PMC

References

    1. Kitiyakara C., Kopp J.B., Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:172–182. doi: 10.1053/snep.2003.50025. - DOI - PubMed
    1. Trautmann A., Bodria M., Ozaltin F., et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015;10:592–600. doi: 10.2215/CJN.06260614. - DOI - PMC - PubMed
    1. Iijima K., Sako M., Nozu K., et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–1281. doi: 10.1016/S0140-6736(14)60541-9. - DOI - PubMed
    1. Ravani P., Bonanni A., Ghiggeri G.M. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol. BMJ Open. 2017;7 doi: 10.1136/bmjopen-2016-013319. - DOI - PMC - PubMed
    1. Ravani P., Lugani F., Drovandi S., et al. Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr. 2021;175:631–632. doi: 10.1001/jamapediatrics.2020.6150. - DOI - PMC - PubMed

Publication types

LinkOut - more resources